An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL ashpublications.org/bloodadvances/…

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richters: These results suggest a proportion of patients derive benefit from CAR-T therapy and emphasize the importance of future prospective trials Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Chronic Lymphocytic Leukemia: survivorship model of care provides an opportunity to deliver a multidisciplinary and holistic approach to optimize outcomes. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Big news for #CLL . Definitely something I will consider for my patients. —> FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory CLL or SLL onclive.com/view/fda-appro…

In this real-world analysis, Kittai et al find that when treated the same, Black patients with CLL have equal outcomes to White patients with CLL. Access to care appears to be one of the main barriers to improving survival for Black patients with CLL.

onlinelibrary.wiley.com/doi/epdf/10.10…

Our #CLL -Lymphoma US agenda is up and ready! 🎊 Take a look at the sneak peak of day 1 below, and if you like what you see, join us in La Jolla!

Sign up is quick and easy, just follow the link: bit.ly/3Hu9yP5

🗓️ When: May 3-4

📍 Location: Estancia La Jolla Hotel, CA